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ABSTRACT
The assessment and management of patients with 
known, or suspected, paediatric inflammatory bowel 
disease (PIBD) has been hugely impacted by the COVID-19 
pandemic. Although current evidence of the impact of 
COVID-19 infection in children with PIBD has provided a 
degree of reassurance, there continues to be the potential 
for significant secondary harm caused by the changes to 
normal working practices and reorganisation of services.
Disruption to the normal running of diagnostic and 
assessment procedures, such as endoscopy, has 
resulted in the potential for secondary harm to patients 
including delayed diagnosis and delay in treatment. 
Difficult management decisions have been made 
in order to minimise COVID-19 risk for this patient 
group while avoiding harm. Initiating and continuing 
immunosuppressive and biological therapies in the 
absence of normal surveillance and diagnostic procedures 
have posed many challenges.
Despite this, changes to working practices, including 
virtual clinic appointments, home faecal calprotectin 
testing kits and continued intensive support from 
clinical nurse specialists and other members of the 
multidisciplinary team, have resulted in patients still 
receiving a high standard of care, with those who require 
face- to- face intervention being highlighted.
These changes have the potential to revolutionise the 
way in which patients receive routine care in the future, 
with the inclusion of telemedicine increasingly attractive 
for stable patients. There is also the need to use lessons 
learnt from this pandemic to plan for a possible second 
wave, or future pandemics as well as implementing some 
permanent changes to normal working practices.
In this review, we describe the diagnosis, management 
and direct impact of COVID-19 in paediatric patients 
with IBD. We summarise the guidance and describe 
the implemented changes, evolving evidence and the 
implications of this virus on paediatric patients with IBD 
and working practices.
BACKGROUND
The prevalence of paediatric inflammatory 
bowel disease (IBD) in the UK is approxi-
mately 0.05%,1 with an estimated incidence 
of 10–12/100 000/year.2 The coronavirus 
(SARS- CoV-2) global pandemic has had a 
significant impact on all aspects of healthcare, 
leading to profound changes in working prac-
tices across all specialties. This resulted in very 
significant changes over a short period of time 
for services to be able to continue to deliver 
the highest standard of care to those who 
needed it. This occurred during a period of 
uncertainty with limited and slowly emerging 
evidence subsequently impacting how these 
changes were made. For children with IBD, 
there were and continue to be significant 
alterations to the diagnostic pathway, assess-
ment and monitoring of disease, including, 
for example, the increased use of virtual 
management and reduced access to diag-
nostic and surveillance endoscopy.
The measures taken to protect this vulner-
able patient group were enacted in order to 
protect from both the harm posed by the virus 
itself and the potential for secondary harm 
from service changes and access to health-
care with a high risk of secondary morbidity. 
During the months of lockdown in the UK, 
diagnostic and monitoring investigations for 
IBD, which were normally widely available, 
were largely reserved for emergency use 
only.3 There continue to be changes to these 
normal working practices as the UK emerges 
from lockdown phases. Figure 1 represents a 
timeline of key events during the COVID-19 
pandemic within the UK.
As the prevalence of the virus reduced in the 
community, our understanding of its limited 
impact on paediatric patients was better 
understood.4 Reassuringly, the emerging 
evidence base from across the world has 
shown that IBD in children is not a risk factor 
for the development of severe infection with 
SARS- CoV-2.5 This is similar in adults.6 The 
Surveillance Epidemiology of Coronavirus 
Under Research Exclusion (SECURE)- IBD 
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database has reported a total of 174 cases of COVID-19 
in under 20- year olds worldwide. So far, only one of 
these cases required intensive care unit admission and 
ventilation and none have died.7 Another study of eight 
children with IBD who contracted SARS- CoV-2 has been 
reported by the Paediatric IBD Porto group of European 
Society of Paediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN). All of these cases had mild symp-
toms, even where IBD treatment with immunomodula-
tors and/or biologics was present.5 6 This evidence can 
provide some degree of reassurance for members of the 
paediatric multidisciplinary team (MDT) and patients 
with IBD alike, however, this must be interpreted with 
some caution as we await more data and potential devel-
opments in this evolving global pandemic.
This review aims to address the current impact of the 
COVID-19 pandemic on the diagnosis, assessment and 
management of paediatric IBD after rapid changes made 
during a period of uncertainty and with evidence of the 
impact of these changes emerging slowly thereafter. 
We suggest strategies to minimise harm and disruption 
to patients caused by the direct and indirect impacts of 
COVID-19, while operating within ongoing restrictions.
Diagnosis of paediatric IBD
Prior to recent changes, the international consensus for 
diagnosing IBD in children with appropriate symptoms, 
signs or supportive laboratory investigations was based 
on the revised Porto criteria,8 a combination of upper 
and lower gastrointestinal endoscopy with small bowel 
imaging—usually by MRI. The pathway to diagnosis for 
an individual patient would often involve review from 
general then specialist clinicians, preliminary investiga-
tions including blood tests and faecal calprotectin (FC), 
then referral to a specialist unit for further assessment 
and investigation, including endoscopy under general 
anaesthetic. Endoscopic assessment, as per revised Porto, 
allows the visualisation of the oesophagus, stomach, 
duodenum, ileum and colon, enabling a robust descrip-
tion of the location and extent of macroscopic disease 
(phenotype) while allowing tissue sampling for histolog-
ical confirmation of disease and formal diagnostic clas-
sification. Phenotype impacts therapeutic options, with 
limited rectal disease being amenable to topical enema 
therapy and more extensive disease prompting consider-
ation of early treatment escalation. The role of endoscopy 
in the initial diagnosis and in guiding treatment decisions 
in paediatric IBD is therefore fundamental.
Investigations for paediatric IBD in the COVID-19 era
Due to the restructuring of services as a result of COVID-
19, clinical examination, laboratory testing, endoscopic 
and radiological tests were all the more difficult to access.3 
More specifically FC testing (which deals directly with 
stool samples) may have caused unnecessary viral expo-
sure to healthcare and laboratory staff and, consequently, 
availability of this test was temporarily affected in a vari-
able manner across the UK.9 Furthermore, face- to- face 
clinic appointments and physical examinations involve 
patient travel, interaction with multiple healthcare staff 
and ultimately increased risk of viral transmission, even 
where appropriate public health measures have been 
implemented, and so were extremely limited and remain 
limited at present.
Delayed diagnosis of paediatric IBD is associated with 
poorer outcomes and higher risks of surgery.10 These 
risks must be carefully weighed up with the potential risk 
posed by COVID-19 to both patients and healthcare staff. 
Furthermore, decisions to defer or expedite diagnostic 
investigations, particularly endoscopy, are extremely diffi-
cult and require multidisciplinary discussion and exper-
tise, informed by current evolving data and evidence.
Impact of COVID-19 on the referral pathway
Paediatric IBD management is through referral networks 
across the UK. These pathways are key to implementing 
safe and timely referrals, alongside continued care. At the 
peak of the pandemic in the UK, there was reduced access 
to baseline tests, such as FC11 and subsequently onward 
referral to gastroenterology, and acceptance/prioriti-
sation of referrals without objective markers suggesting 
IBD may have been delayed. The impact of this period on 
diagnosis and disease progression will require assessment 
once diagnostic catch- up is complete and all cases have 
sufficient follow- up data to look at outcomes.
Guidance on the use of endoscopy
The ESPGHAN published guidance on the use of endos-
copy in April 2020, at an early stage of the COVID-19 
pandemic in Europe. This guidance stated that ‘all 
endoscopy except emergency and essential procedures 
Figure 1 Timeline of major UK events in relation to the COVID-19 pandemic, December 2019–September 2021.
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should stop immediately’.12 This was in keeping with the 
virtual cessation of endoscopy in adult practice.13
The British Society of Gastroenterology and Joint Advi-
sory Group (BSG- JAG) released a statement on 3 April 
2020, which stated that all endoscopic disease assessments 
for IBD, surveillance endoscopies (IBD) and all symp-
tomatic routine endoscopy referrals should be deferred 
until further notice. This was in line with UK govern-
ment advice ‘to reduce any non- essential exposure to the 
COVID-19 virus and to take all reasonable measures to 
limit its spread’.13 The BSG published new guidance on 
28 August 2020 that outlines specific COVID-19 infec-
tion prevention strategies within endoscopy units across 
the UK. The guidance recommends routine screening 
of patents 3–7 days prior to endoscopy, with COVID-19 
testing occurring 1–3 days prior to the procedure. Addi-
tional self- isolation for 7–14 days prior to the proce-
dure is not needed. In centres not performing routine 
COVID-19 testing, patients should self- isolate for 14 days 
prior to the procedure. This guidance allows for more 
endoscopic procedures to take place where risk stratifica-
tion and testing are implemented.14
SARS- CoV-2 is mainly spread through droplets that 
enter the respiratory tract, however, viral RNA can also 
be found within stool,15 though whether this remains 
infectious is subject to ongoing research and is not yet 
clear. To date, a single case report has determined that 
live viruses can be present in the stool of a patient with 
severe COVID-19.16
Upper gastrointestinal endoscopic procedures are 
‘aerosol- generating’, increasing the chance of respiratory 
droplet viral transmission to healthcare staff, something 
amplified by the prevalent use of general anaesthetic 
for endoscopies in paediatric practice. Whether lower 
gastrointestinal endoscopy poses a risk for transmis-
sion remains uncertain but this is not in itself currently 
deemed ‘aerosol- generating’.15
Guidance published by BSG- JAG and ESPGHAN was 
used by clinicians to aid their decisions to either defer 
or initiate diagnostic investigations among uncertain 
evidence at the peak of the pandemic. This may have 
meant that patients with severe symptoms and high 
biomarkers were brought in for an endoscopy, whereas 
those with milder symptoms and borderline markers 
were deferred indefinitely or treated empirically.15
Personal protective equipment requirements
Guidance from BSG states that if a patient has been asymp-
tomatic, tested negative in the preceding 48–72 hours and 
has no history of potential contact/exposure to infection, 
then standard personal protective equipment (PPE) can 
be justified. Those who do not meet these criteria should 
be carefully considered and deferred where possible. 
Enhanced PPE includes the use of double gloves and an 
FFP-3 mask and should be worn in the case of an essen-
tial or an emergency procedure, and where possible, 
this should take place in a separate location to those in 
the low- risk category.14 The guidance includes increased 
cleaning and, therefore, increases delays between cases in 
theatre. Careful selection of patients is, therefore, crucial 
to protect patients, staff and the PPE supply chain.14 17 
As the evidence base improves with time, this guidance 
is likely to evolve to further maximise access to endos-
copy in both a safe and timely manner while protecting 
patients and staff.
Management of paediatric IBD
Facilitating safe and holistic management of known 
patients with IBD has proved challenging. Services have 
relied on virtual infrastructure and initial uncertainty 
among healthcare professionals and patients/families 
was unavoidable.
Immunosuppressive therapies and COVID-19
Data from SECURE- IBD7 and adult cohorts18 suggest 
that the risk from IBD therapies is limited, with steroids 
conferring the highest risk. Paediatric patients were 
largely unaffected by COVID-19, with only 29 reported 
cases, of which 3 were hospitalised and none required 
ventilation or intensive care.19 By stopping medications, 
patients can potentiate disease flares that are associated 
with increased immunocompromise, potential exposure 
to high- dose steroids, increased infection risk, the need 
for hospitalisation and intervention.20 21 There has under-
standably been a significant amount of anxiety among 
clinicians, patients and their families; however, children 
should continue their medications as normal.22
Recent expert guidance on the management of acute 
severe colitis in adults, and subsequently in children, 
largely supports the continuation of existing therapeutic 
approaches, including intravenous steroids and escala-
tion to infliximab as appropriate.23 24
Facilitating and monitoring ongoing maintenance therapy
Monoclonal infusion services were reorganised as a 
priority to accommodate social distancing, limit patient 
journeys and minimise hospital exposure. This was done 
by moving these services to ‘cold’ areas. The focus on 
providing these services was clear from the start and 
allowed therapy to continue as required with minimal 
disruption.25
Thiopurines, including azathioprine and mercapto-
purine, are used in paediatric IBD to maintain disease 
remission. These drugs have a significant side effect 
profile, so robust blood monitoring is necessary.26 During 
the COVID-19 era, the services to provide these blood 
tests were reorganised to allow for social distancing, 
with many patients still attending specialist centres, or 
in some cases, their local general practitioner (GP).25 
This required extensive planning across each network to 
ensure these services remained in place and patients on 
long- term treatments were kept safe.
Decision making for patients with IBD often uses endo-
scopic assessment, both with a view to escalation and in 
the assessment of response to therapy. Cessation of endos-
copy during lockdown may have prevented adequate 
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assessment and escalation for patients, with downstream 
effects not yet felt. The backlog of patients requiring 
routine endoscopic assessment is a vital consideration in 
recovery planning.
Role of the MDT
Paediatric IBD MDTs must carefully weigh up the risks of 
initiating treatments against the perceived benefits while 
doing so with reduced endoscopic capacity and so less 
diagnostic/phenotypic fidelity. Initiating new therapies 
during the COVID-19 era may therefore prove more diffi-
cult. It has become increasingly evident that continued 
expertise and intensive support from the IBD nursing 
team is fundamental to supporting patients and families 
during the pandemic, particularly because these profes-
sionals act as a lead point of contact and so receive the 
majority of queries/concerns from patients and families 
during a time of profound uncertainty. Allied health 
professionals, including psychology and dietetics, have 
continued to support patients and clinicians during the 
pandemic. These services have largely become virtual, 
with specific patients being reviewed face to face.27
Changes to clinic appointments
Many outpatient clinic appointments for new or follow- up 
patients have been switched to web- based consulta-
tions or telephone appointments. Importantly, this has 
happened rapidly and without significant infrastructure 
investment, staff retraining or job plan consideration. 
This has however facilitated social distancing, helped 
minimise the risk of infection for patients and staff and 
has allowed clinical care to continue with regular inter-
vals and contact. A plan for any additional information 
needed (bloods or FC) can be arranged during such 
appointments while attendance at physical clinics has 
largely been reserved for acutely unwell patients, limiting 
patient numbers and allowing these reviews to be 
supported in line with established COVID-19 protocols in 
each National Health Service (NHS) trust area. Switching 
to virtual consultations has facilitated continued contact 
and has been well received by most patients and medical 
professionals.28 29 It has meant that there was no need to 
stop follow- up completely. Contact points, usually in the 
form of the IBD nurse team email/telephone advice line, 
must continue to be made available to patients and their 
families as a priority service provision.25 These services 
are commonly used to deliver rescue advice to patients 
experiencing disease flares or increased symptoms. 
In addition to providing monitoring advice, they also 
provide a conduit for rapid review and treatment.25
Self-monitoring of disease activity: home FC testing
FC is a useful marker of intestinal inflammation and has 
been shown to correlate well with endoscopic inflam-
mation in IBD.11 Normally, FC testing is carried out as 
an ELISA test, which is considered the gold- standard 
method.30 This must be done in a laboratory setting, 
which is a potentially high risk for the transmission of 
SARS- CoV-2 virus25 (involving stools) and so has been less 
widely available in many areas due to risk assessments or 
restructuring within hospital laboratory services. Home 
FC testing kits have been used as a substitute for some 
paediatric patients with IBD during this time. These kits 
have been tested in a number of trials comparing their 
results with the ELISA test with promising outcomes. 
One study of 221 patients with IBD found the CalproS-
mart test to have a moderate yet clinically relevant agree-
ment with the ELISA test, with a sensitivity of 82% and 
specificity of 85%.30 Further studies have suggested that 
the home IBDoc testing kits agree with ELISA tests at FC 
levels below 500 µg/g.31
Home testing kits have been used in a specific cohort 
of patients to allow for surveillance at home, monitoring 
of treatment responses and (in combination with labora-
tory FC testing) flare detection requiring treatment esca-
lation. An investigation into the feasibility of home FC 
testing concluded that 80% of parents felt this method 
would improve disease management, however, the prac-
ticality of using them was difficult for over half.32 This 
method of testing allows for greater patient empow-
erment with reduced embarrassment, especially for 
adolescents, perhaps leading to better compliance. The 
technology also allows smartphone apps to communicate 
results directly and immediately to the patient’s MDTs, 
increasing efficiency and potentially also the speed 
of clinical reaction to elevated results. Coordinating 
the distribution of kits, providing support/education 
on their use and integrating their results into the clin-
ical record and MDT forum are crucial roles that need 
specific thought prior to the use of such kits in practice. 
Despite the administrative nature of these tasks, many of 
these roles will naturally fall into the IBD nursing service 
but this is likely to already be under considerable pres-
sure from other service alterations and pressures during 
a period of considerable flux.
Moving into the ‘recovery phases’
As we move forward in our clinical response to COVID-
19, the guidance surrounding the use of endoscopy is 
changing and will continue to evolve.33 Following the 
suspension of all but emergency and essential proce-
dures, an early ‘recovery phase’ was implemented in the 
UK on 30 April 2020. In the context of paediatric IBD, 
this phase allowed for some new diagnostic and assess-
ment endoscopies to take place, where clinical manage-
ment will be influenced. Despite this, access to endos-
copy remains variable and requires careful senior deci-
sion making, with reorganisation of services and staff, 
PPE considerations and patient screening all requiring 
consideration.17 An additional consideration for day- case 
endoscopy procedures and intravenous infusions is the 
requirement for social distancing within units. As the 
number of lists returns towards normal, patient numbers 
are generally lower per list, resulting in an increased 
need for theatre time, an important consideration in the 
recovery phase.
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Screening and testing prior to endoscopy are crucial 
steps in the prevention of transmission of COVID-19. 
Table 1 shows the SCOTS criteria, which can be used to 
screen patients over the phone 3–7 days prior to endos-
copy and can be used where testing is not available to 
stratify risk. Where testing is available, this should be 
done 1–3 days prior to the procedure and all positive or 
‘high- risk’ (scoring ≥1 SCOTS) patients deferred where 
possible, or endoscopy carried out at a ‘hot’ location 
specific for high- risk patients.17 In reality, the use of ‘hot’ 
location endoscopy is unlikely to be required or feasible 
for the majority of paediatric patients and is more 
amenable to an adult practice.
COVID-19 risk and specific management considerations
During the initial phase of the pandemic, there was an 
evolution of guidance as increased evidence emerged. 
It seems evident that active IBD puts adult patients at 
greater risk of infection with COVID-19 both within 
the hospital and in the community.34 Despite this, the 
largest dataset on over 170 children with IBD did not 
demonstrate any deaths associated with COVID-19 and 
only a single patient required ventilation.7 Within adult 
patients, the use of corticosteroids, but not antitumour 
necrosis factor (anti- TNF) agents, was associated with 
increased morbidity and mortality, but this was not borne 
out in paediatric disease.19 The BSG produced guid-
ance to classify patients with IBD on immunosuppressive 
‘risk’15 and the measures that should be followed, with 
some patients requiring shielding during the initial phase 
of the pandemic.22 35 This was also adapted by Crohn’s 
and Colitis UK to provide a useful flowchart for patient 
use.22 This information was not specifically targeted to 
paediatric patients and the guidelines were adapted by 
the BSPGHAN to reflect paediatric practice.36 In many 
cases, clinical teams were required to discuss their patient 
groups and come to their own MDT decisions on patients 
at the highest risk. Clear government advice was made 
available through the initial lockdown phases for those 
in high- risk groups. Following the UK- wide removal of 
shielding for all patients in August 2020 at the time of 
writing, there are no paediatric patients with IBD, regard-
less of therapy, requiring specific COVID-19 precautions.
Shielding in children
Shielding of a small group of patients with IBD consid-
ered extremely vulnerable (steroid therapy, active 
disease, newly started on anti- TNF) was practised from 
March to August 2020, with the need to shield ending at 
this point. The practicalities of implementing shielding 
guidance for children and families is particularly chal-
lenging and specific guidance on this is lacking.37 Recent 
data would suggest that many paediatric patients, even 
within the vulnerable ‘shielding’ group, are not at 
increased risk of severe COVID-19 and current guidance 
indicates that shielding will not be needed for paediatric 
patients with IBD in the event of a second wave, although 
as evidence evolves this may change. In many house-
holds, it is impossible for children to stay 1 or 2 m away 
from their parents and siblings, particularly if they are 
very young. Clinical teams must take this into considera-
tion and take a pragmatic approach to advising parents 
on how they can reduce the risk of infection for their 
child while still maintaining family life. Shielding has a 
profound impact on the quality of life. The Royal College 
of Paediatrics and Child Health (RCPCH) continues to 
work with paediatric specialties to review and revise the 
need for shielding in those who were initially thought to 
be clinically extremely vulnerable.37
Returning to school
Many young people and parents of children with chronic 
conditions, such as IBD, will be anxious about schools 
beginning to reopen. The balance of possible risks 
of COVID-19, against the long- term impact of lack of 
schooling, is complex, with difficulties in enforcing 1–2 m 
social distancing, especially between young children and 
teachers. UK- wide guidance from the RCPCH, based on 
the most contemporary evidence,4 encourages all chil-
dren with IBD to return to school. Children who were 
identified as ‘clinically extremely vulnerable’ in March 
2020, and were therefore previously advised to shield, can 
return to school as normal at present. However, if the UK 
government changes shielding advice, those children who 
are still identified as ‘clinically extremely vulnerable’ may 
no longer be able to attend school. It is becoming increas-
ingly clear that primary school children are much more 
likely to benefit from the return to school than they are 
to come to significant harm.38 It must be acknowledged 
that the practicalities of all children returning to school 
are complex, and there is likely to be significant anxiety 
for patients and families in specific scenarios. In May 
and September 2020, BSPGHAN produced specific guid-
ance for returning to school, providing a framework for 
patients, families and clinicians to approach this topic.39
Table 1 SCOTS criteria (adapted from tHayee B, et al 2020.)41
SCOTS criteria Points if ‘yes’
In the last 14 days has the patient had SYMPTOMS suggestive of COVID-19? 1
In the last 14 days has the patient come into close CONTACT with a known or suspected case of COVID-19? 1
Does the patient’s OCCUPATION mean they have been exposed to COVID-19? 1
Has the patient TRAVELLED and returned from a known risk area? 1
Is the patient in a ‘SHIELDED’ category? 1
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The indirect impact of the pandemic on children is 
now being felt. There is likely to be significant anxiety 
regarding returning to school and normal activities for 
some patients with IBD. It is clear that recovery planning 
of services and returning to normal should include the 
patient’s opinions.40
Surgery and radiological investigations
Recent data indicated that most IBD centres across 
the UK maintained surgical and radiological services, 
even during lockdown.27 However, these were largely 
reduced and planned non- emergency surgery was 
delayed. District general hospitals had worse access 
to radiological investigations. The long- term sequelae 
of delayed surgery and the inability to identify small 
bowel disease, stricturing disease or complex fistu-
lating disease will need to be carefully evaluated in 
order to mitigate against harm.
Long-term effects on patients with IBD and mitigating 
strategies
With every change to the normal running of services, there 
is the question of the longer- term impact on patients. 
Those waiting on diagnosis with milder symptoms may 
have their diagnostic testing deferred for a longer period. 
Patients with delayed diagnosis and prolonged time to 
initiate treatment are likely to have a direct impact on 
long- term care and disease management. There may be 
an observed decrease in suspected cases as parents put off 
consulting with their GPs regarding their child’s symp-
toms. This could either be due to a misunderstanding 
that these services are not currently available or because 
of anxiety surrounding viral transmission. These miscon-
ceptions may lead to an increased number of new cases 
of IBD following this pandemic due to delayed diagnosis, 
alongside a backlog of investigations that have been put 
on hold during this time.
Although it is easy to look at the negative effects, the 
positives should be highlighted. In the future, children 
with a mild IBD phenotype or those who are stable and 
in remission may be able to switch to telephone or virtual 
appointments to avoid regular travel to specialist centres. 
Home FC testing could also be used more frequently, 
with results being immediately communicated to the 
MDT for discussion and therapeutic planning. Patients 
who remain stable and in remission could continue with 
home testing and possibly reduce their need for face- to- 
face appointments in the long term.
Planning for a second wave
The possibility of a second wave of infection, or a contin-
uation of the initial wave, requiring repeated local or 
national lockdowns, remains. Using what we have learnt 
from the initial wave and lockdown is vital to provide 
the best level of care possible to new and known paedi-
atric patients with IBD This includes the clear need to 
maintain endoscopy services, prioritising assessment of 
acutely unwell patients, limiting the need for any form 
of ‘shielding’ and continuing with monoclonal therapy. 
Data on paediatric IBD in COVID-19 remain reas-
suring and there are positive consequences including 
the advancement of virtual clinics and support services, 
however, rigorous evaluation of outcomes, including 
patient opinions, will be required prior to routine 
implementation. A specific consideration in the event 
of increased COVID-19 cases will be streamlining of pre- 
endoscopy COVID-19 testing to ensure that services can 
continue. Additional consideration of ‘cold’ non- COVID 
hospitals to continue planned procedures may become 
more important.
Beyond this, formulating guidelines for future 
pandemics will allow structured and safe implementa-
tion of management strategies in the event that another 
unforeseen infectious disease sweeps the globe. This will 
also allow new working practices to become embedded 
within the NHS for years to come, using the latest tech-
nology to the benefit of patients, carers and the wider 
MDT. This will require extensive administrative support 
and careful planning.
CONCLUSION
With the forced reorganisation of multiple services across 
the UK, the direct and indirect impact of the COVID-19 
pandemic on children with diagnosed or suspected 
IBD must not be overlooked. Paediatric IBD teams face 
ongoing difficult decisions, including which patients 
require treatment initiation or a change in therapy, with 
limited access to specific tests that are usually imperative 
to making these choices.
The long- term impact of COVID-19 on the running 
of paediatric IBD services will pose many challenges to 
patients and families. Despite this, the strategies imple-
mented to continue monitoring patients during the lock-
down, through minimising trips to the hospital, has the 
potential to revolutionise the way in which they could be 
managed in the future. Continuing the use of home FC 
testing kits, virtual appointments and email/telephone 
advice to support the paediatric patient with IBD group 
will allow for greater patient and family empowerment 
with fewer clinic visits. This is a complex system and the 
logistics of having multiple clinic modalities in the long 
term would require extensive planning and consider-
ation within the MDT.
There is increasingly reassuring evidence from 
across the world of the lack of direct impact of 
COVID-19 on patients with IBD. The indirect impact 
of reorganisation of healthcare during the pandemic 
has, however, had a significant impact on patients. It 
is imperative professional societies continue to guide 
paediatric IBD teams as departments enter a ‘recovery 
phase’ in order to protect staff, patients and the wider 
community from the effects of this global pandemic. It 
is likely the lessons learnt from COVID-19, though not 
yet fully established, will remain far longer lasting than 
the pandemic itself.
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